Are all the hypertensives made equal

作者: Arnljot Flaa , Sverre E. Kjeldsen

DOI: 10.1007/S00059-006-2782-1

关键词:

摘要: Blood pressure lowering in hypertensive patients is of significant importance. The complex pathophysiology makes the therapeutic targets many, and extensive research has provided us with many antihypertensive drugs. However, data indicate that proportion controlled blood far from satisfying. This may partly be explained by a lack individualized treatment. Present guidelines for management hypertension emphasize thorough evaluation patient necessary before initiating Based on information about gender, age, ethnicity, family history, clinical examination concomitant diseases like diabetes mellitus, coronary heart disease, failure, cerebrovascular disease gout, physician able to provide best most need two three drugs control pressure. Thus, we methods predict responses various individual patients. Possibly, future treatments based upon genetic variants. Until now, several polymorphisms genes regulating have been located, these influence results are heterogeneous contradictory, yet not capable determining treatment properties. Coming years challenge further clarify potentially important aspects Meanwhile, physicians obligated individualize other means, examination.

参考文章(60)
Ehud Grossman, Franz H Messerli, Diabetic and Hypertensive Heart Disease Annals of Internal Medicine. ,vol. 125, pp. 304- 310 ,(1996) , 10.7326/0003-4819-125-4-199608150-00009
Miwa Sasaki, Takashi Oki, Arata Iuchi, Tomotsugu Tabata, Hirotsugu Yamada, Kazuyo Manabe, Kazuyo Fukuda, Miho Abe, Susumu Ito, Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. Journal of Hypertension. ,vol. 14, pp. 1403- 1408 ,(1996) , 10.1097/00004872-199612000-00003
Alberto Zanchetti, Lennart Hansson, Denis Clement, Dag Elmfeldt, Stevo Julius, Telma Rosenthal, Bernard Waeber, Hans Wedel, THE HOT INVESTIGATORS, including F Portaluppi, None, Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? Journal of Hypertension. ,vol. 21, pp. 797- 804 ,(2003) , 10.1097/00004872-200304000-00024
Michael de Swiet, Maternal blood pressure and birthweight. The Lancet. ,vol. 355, pp. 81- 82 ,(2000) , 10.1016/S0140-6736(99)00288-3
J. Stokes, W. B. Kannel, P. A. Wolf, R. B. D'Agostino, L. A. Cupples, Blood pressure as a risk factor for cardiovascular disease. The Framingham Study--30 years of follow-up. Hypertension. ,vol. 13, ,(1989) , 10.1161/01.HYP.13.5_SUPPL.I13
Philip B Mellen, David M Herrington, Pharmacogenomics of blood pressure response to antihypertensive treatment. Journal of Hypertension. ,vol. 23, pp. 1311- 1325 ,(2005) , 10.1097/01.HJH.0000173510.52987.68
Michael A Weber, Stevo Julius, Sverre E Kjeldsen, Hans R Brunner, Steffan Ekman, Lennart Hansson, Tsushung Hua, John H Laragh, Gordon T McInnes, Lada Mitchell, Francis Plat, M Anthony Schork, Beverly Smith, Alberto Zanchetti, Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. The Lancet. ,vol. 363, pp. 2049- 2051 ,(2004) , 10.1016/S0140-6736(04)16456-8
Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke, Tomas Berl, Marc A. Pohl, Julia B. Lewis, Eberhard Ritz, Robert C. Atkins, Richard Rohde, Itamar Raz, Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes The New England Journal of Medicine. ,vol. 345, pp. 851- 860 ,(2001) , 10.1056/NEJMOA011303
Patricia M Kearney, Megan Whelton, Kristi Reynolds, Paul K Whelton, Jiang He, Worldwide prevalence of hypertension: a systematic review. Journal of Hypertension. ,vol. 22, pp. 11- 19 ,(2004) , 10.1097/00004872-200401000-00003